BioForce Nanosciences Holdings, Inc.
BFNH
$0.60
$0.2466.67%
| Weiss Ratings | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.19 | |||
| Price History | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -5.96% | |||
| 60-Day Total Return | -33.33% | |||
| 90-Day Total Return | -25.00% | |||
| Year to Date Total Return | -10.41% | |||
| 1-Year Total Return | -67.39% | |||
| 2-Year Total Return | -75.51% | |||
| 3-Year Total Return | -56.83% | |||
| 5-Year Total Return | -24.05% | |||
| 52-Week High % Change | -71.01% | |||
| 52-Week Low % Change | 267.87% | |||
| Price | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.07 | |||
| 52-Week Low Price | $0.16 | |||
| 52-Week Low Price (Date) | Jul 31, 2024 | |||
| 52-Week High Price (Date) | Jun 21, 2024 | |||
| Valuation | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 17.56M | |||
| Enterprise Value | 17.82M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | 1.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -8.06 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.60 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -37.00 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 29.27M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 757 306 6090 | |||
| Address | 2020 General Booth Boulevard Virginia Beach, VA 23454 | |||
| Website | www.bioforceeclipse.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26,173.91% | |||
| Return on Equity | -- | |||
| Income Statement | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -481.60K | |||
| Net Income (TTM) | -481.60K | |||
| Net Income Avl. to Common (TTM) | -481.60K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -7.39% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | -7.69% | |||
| Balance Sheet | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.60K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 1.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.18M | |||
| Current Ratio (Q) | 0.001 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 1.60K | |||
| Total Current Liabilities (Q) | 2.18M | |||
| Total Debt (Q) | 260.00K | |||
| Total Liabilities (Q) | 2.18M | |||
| Total Common Equity (Q) | -2.18M | |||
| Cash Flow | BFNH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 54.40K | |||
| Net Change in Cash (TTM) | 1.00K | |||
| Levered Free Cash Flow (TTM) | 127.10K | |||
| Cash from Operations (TTM) | -53.50K | |||
